X4 Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- X4 Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- XFOR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001501697
Board of directors
-
Adam R. Craig · Director · Executive ChairmanSince 2025
-
Alison Frances Lawton · DirectorSince 2023
-
Craecker Francoise De · DirectorSince 2023
-
David W. J. Mcgirr · DirectorSince 2023
-
Gary Bridger · DirectorSince 2023
-
Keith Woods · DirectorSince 2023
-
Kelly Gold · DirectorSince 2026
-
Michael S. Wyzga · DirectorSince 2023
-
Murray Stewart · DirectorSince 2023
-
Paula Ragan · Director · President and CEOSince 2023
-
William Aliski · DirectorSince 2023
Chief executives
Paula Ragan
· President and CEO
Dates unknown
Board connections
6 of this board's directors also sit on 13 other boards.
- via Murray Stewart and Paula Ragan
- via Murray Stewart
- via Alison Frances Lawton
- via David W. J. Mcgirr
- via Michael S. Wyzga
- via Michael S. Wyzga
- via Keith Woods
- via Alison Frances Lawton
- via David W. J. Mcgirr
- via Keith Woods
- via Alison Frances Lawton
- via Keith Woods
- via Michael S. Wyzga
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $249,997
- 1 purchase by 1 insider
- Sold, last 12 months
- $429,248
- 4 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 12, 2026 | Adam R. Craig Director, Officer (Executive Chairman) | Open-market sale | −47,436 | $4.44 | $210,829 |
| Aug 12, 2026 | Volpone John Officer (President) | Open-market sale | −24,576 | $4.44 | $109,228 |
| Jun 30, 2026 | KIRSKE DAVID Officer (Chief Financial Officer) | Open-market sale | −8,543 | $4.26 | $36,428 |
| May 12, 2026 | KIRSKE DAVID Officer (Chief Financial Officer) | Open-market sale | −16,961 | $4.29 | $72,763 |
| Oct 23, 2025 | Adam R. Craig Director, Officer (Executive Chairman) | Open-market purchase | +86,206 | $2.90 | $249,997 |
| Aug 14, 2025 | Volpone John Officer (President) | Grant or award | +289,881 | — | — |
| Aug 14, 2025 | Adam R. Craig Director, Officer (Executive Chairman) | Grant or award | +289,881 | — | — |
| Aug 14, 2025 | KIRSKE DAVID Officer (Chief Financial Officer) | Grant or award | +193,254 | — | — |
| Jun 9, 2025 | Murray Stewart Director | Grant or award | +1,500 | — | — |
| Jun 9, 2025 | Craecker Francoise De Director | Grant or award | +1,500 | — | — |
| Jun 9, 2025 | Gary Bridger Director | Grant or award | +1,500 | — | — |
| Jun 9, 2025 | Keith Woods Director | Grant or award | +1,500 | — | — |
| Jun 9, 2025 | David W. J. Mcgirr Director | Grant or award | +1,500 | — | — |
| Jun 9, 2025 | Michael S. Wyzga Director | Grant or award | +1,500 | — | — |
| May 20, 2025 | Thoren Natasha Fay Officer (Chief Legal Officer) | Grant or award | +3,333 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.